Oxford BioTherapeutics' Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3

First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development Obrixtamig reaches late-stage development triggering milestone paymentContinued clinical progress across the partnered programmes demonstrates the strength and productivity of the long-standing OBT-Boehringer Ingelheim collaborationOxford, UK, and San Jose, California, 22 June 2026 - Oxford BioTherapeutics ("OBT”), a clinical-